For a long time, the honest answer for many Indian families was no. The most advanced options sat behind flights, visas, foreign hospital admissions, and costs that put them out of reach for all but a small number of people. That is beginning to change.
Why Some Leukaemia Cases Are Harder to Treat
Most patients with Acute Lymphoblastic Leukaemia begin treatment on a standard chemotherapy protocol and for many, that protocol works. But leukaemia does not always follow the expected path. Some patients relapse. Some stop responding to the drugs that once worked. For those families, the question of what is still possible becomes the only one that matters and until recently, the answers available in India were limited.
The Treatment That Is Changing the Odds
Over the past two years, a small number of Indian centres have begun offering CAR-T cell therapy for leukaemia, a treatment that was largely unavailable in the country before that.
The way it works is straightforward to explain, even if the science behind it is not. The patient's own immune cells are collected, reprogrammed to find and attack the leukaemia cells that chemotherapy could not reach and returned to the body. The immune system then does what it was never able to do before. In patients with relapsed B-cell leukaemia, this approach has produced remission in 80 to 90 percent of cases, a number that means everything to families who had been told there was nothing left to try.
India now has its own approved product for this therapy. India now has an approved indigenous CD19 CAR T-cell therapy , making this advanced treatment more accessible for eligible patients within the country.
SunAct Cancer is among the handful of Indian centres currently equipped to administer it.
What the Treatment Journey Looks Like
The process spans several weeks. Cells are collected in a short-stay procedure that most patients find far less daunting than they expected. Those cells are then engineered over two to four weeks in a lab. When they are ready, the patient goes through a short course of conditioning treatment before the infusion itself, which takes only a few hours. After that, the medical team monitors the patient closely for about two weeks as the immune response builds.
What happens after discharge matters as much as what happens during treatment. Check-ins, blood tests, and bone marrow assessments typically continue for years, this is not a therapy where a family is handed a discharge summary and left to manage the rest on their own.
Understanding the Side Effects
Centres delivering this therapy are upfront with families about what to expect. The main side effects are well documented and are watched for closely from the moment of infusion. Most patients manage them without serious complications when the treating team has handled these responses before, which is precisely why the therapy is currently offered at only a small number of specialised centres rather than every hospital.
What Families Should Look for in a Treatment Centre
Because CAR-T therapy is still available at only a handful of hospitals in India, the details of where it is delivered matter almost as much as the therapy itself. A few things consistently come up when families and doctors discuss what makes a difference:
- Continuity of care. The specialists who assess a patient are ideally the same ones who treat them through every stage, rather than passing the case between departments.
- Integrated facilities. CAR-T therapy, bone marrow transplantation and other blood cancer treatments are best delivered under one roof, so families are not moving between hospitals for different parts of the same treatment plan.
- Multidisciplinary approach. CAR-T therapy involves more than a single specialist. A coordinated team of doctors, nurses, and allied healthcare professionals works together to support patients from evaluation and treatment through recovery and long-term follow-up.
- Purpose-built infrastructure. Sterile environments and specialised isolation rooms are not something a general hospital ward can simply add on, they need to be designed for this kind of work from the outset.
- Long-term follow-up. Because outcomes are monitored for years after treatment, centres with a structured follow-up programme tend to catch complications earlier.
Why This Matters for Indian Families
Two years ago, a family considering CAR-T therapy for leukaemia had little choice but to look abroad. That is no longer true. The expertise now exists within India, the infrastructure to deliver it safely has been built, and the cost is a fraction of what international treatment would have required without the added burden of travel, visas, and unfamiliar hospital systems during an already difficult time.
The Families Who Come to SunAct
They come from Mumbai and from cities much further away. Some come after months of searching. Some come because another doctor referred them. Some come because someone they knew went through treatment here and told them about it.
What they find is a centre where the doctors know their names, where the conversations are honest, and where the treatment available is genuinely among the best in the world. Not among the best in India. Among the best in the world, delivered here in Mumbai, by people who built this place because they believed it was possible.
To learn more about acute lymphoblastic leukaemia, explore the educational resources in our Information Centre:
Websites: https://sunactcancer.com/acute-lymphoblastic-leukemia/ | https://sunactcancer.com/car-t-cell-therapy-for-leukemia-in-india/
Disclaimer: This is a sponsored press release. The publisher does not in any manner whatsoever endorse/subscribe to the contents of this article and/or views expressed herein. Reader discretion is advised.
